Indication
Hormone Receptor Negative Tumor
2 clinical trials
41 products
11 drugs
Clinical trial
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy (FASCINATE-N)Status: Recruiting, Estimated PCD: 2024-09-01
Drug
LHRH agonistClinical trial
I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)Status: Recruiting, Estimated PCD: 2030-12-01
Product
Standard TherapyProduct
AMG 386Product
AMG 479Product
MK-2206Product
AMG 386 + TrastuzumabProduct
T-DM1 + PertuzumabProduct
Pertuzumab + TrastuzumabProduct
GanetespibProduct
ABT-888Product
NeratinibProduct
PLX3397Product
PembrolizumabProduct
Talazoparib + IrinotecanProduct
Patritumab and TrastuzumabProduct
SGN-LIV1AProduct
Durvalumab + OlaparibProduct
LetrozoleProduct
Nab paclitaxelProduct
SD-101 + PembrolizumabProduct
CemiplimabDrug
AN0025Product
TrilaciclibDrug
EpirubicinDrug
cyclophosphamideProduct
FluzoparibProduct
SYD985Drug
HER2 ADCDrug
AmcenestrantProduct
Amcenestrant + AbemaciclibProduct
Amcenestrant + LetrozoleDrug
ARX788Product
ARX788 + CemiplimabProduct
VV1 + CemiplimabProduct
Datopotamab deruxtecanProduct
ZanidatamabDrug
LasofoxifeneProduct
Z-endoxifenProduct
ARV-471Product
ARV-471 + LetrozoleProduct
DalpiciclibProduct
PyrotinibDrug
SHR-A1811Drug
AnlotinibProduct
CamrelizumabProduct
PertuzumabDrug
Trastuzumab